New Investigational drug study for Focal Segmental Glomerulosclerosis (FSGS)
- Trial ID:
- IRB-25-8548
- Zhabiz Solhjou, MD
Inclusion Criteria
Patients must:
- Be 18-80 years old
Have a diagnosis of Focal Segmental Glomerulosclerosis (FSGS)
Take or be willing to take an angiotensin II receptor blocker (ARB)
Take < 10mg per day of a corticosteroid.
Be willing to use contraceptives during the length of the study.
Exclusion Criteria
Patients must not:
- Have FSGS secondary to another condition.
Be pregnant or plan to become pregnant during the length of the study.
Have had an organ or a stem cell transplant. (Corneal transplants are permitted.)
Have a history of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus.
Have a history of lymphoma, leukemia, or any active malignancy within the past 2 years.
Have a clinically significant hepatobiliary disease or nephrotic syndrome.
Have a history of alcohol misuse or substance abuse within the past 12 months.
Additional Info
For more information search NCT05183646 at www.clinicaltrials.gov